Dr. Loberg previously served on the Board of Directors of ArQule, a biopharmaceutical company that was acquired by Merck in January 2020, and was also a member of its Compensation, Nominating and Governance Committee and Science Committee. Dr. Loberg has also held a number of senior management positions at Bristol-Myers Squibb, including President of Bristol-Myers Squibb’s Oncology and Immunology, U.S. Primary Care, Northern Europe, Specialty Pharmaceuticals and Squibb Diagnostics divisions, as well as Director and Vice President, E.R. Squibb & Sons Research and Development. Dr. Loberg previously served on the Board of Directors and as Interim Chief Executive Officer of Inotek Pharmaceuticals and as Chief Executive Officer and a member of the Board of Directors of NitroMed. Dr. Loberg received a B.S. in Chemistry from Trinity College and a Ph.D. in Chemistry from Washington University in St. Louis.
Michael Loberg, Ph.D.